Item 7.01 Regulation FD Disclosure

On February 26, 2020, Agile Therapeutics, Inc. (the "Company") updated its corporate presentation that it intends to use at conferences and in meetings with investors. The updates include information on the approval of its first product, its plan for the commercialization of that product and recent financing activities, including the net proceeds from its recent public offering of common stock, which included the exercise in full by the underwriters of their option to purchase additional shares of common stock. The aggregate net proceeds to Agile Therapeutics from the offering were approximately $48.4 million, after deducting underwriting discounts, commissions, and estimated offering expenses. The Company is furnishing herewith a copy of the corporate presentation, which is attached hereto as Exhibit 99.1.

In accordance with General Instructions B.2 and B.6 of Form 8-K, the information included in this Item 7.01 (including Exhibit 99.1 attached hereto), shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.





(d)      Exhibits.



Exhibit
Number                                  Description
  99.1       Agile Therapeutics, Inc. Corporate Presentation dated February 26,
           2020.

© Edgar Online, source Glimpses